Cambridge Epigenetix: Peter Fromen

Jun 14, 2022

Cambridge Epigenetix has appointed Peter Fromen as its CEO effective July 18. Current acting CEO Gail Marcus will continue as chair of the board. Fromen previously served as chief commercial officer of PacBio. Prior to that, he worked at Illumina, where he held leadership roles in investor relations, product marketing, market development, and enterprise sales. As Illumina's global vice president of population genomics and precision health, Fromen oversaw the firm's partnership with Genomics England and the National Health System to execute the 100,000 Genomes Project which led to the commissioning of whole genome sequencing in the NHS for rare diseases and certain cancers.

Cambridge Epigenetix: Peter Fromen

Cerebral Palsy Sequencing Study Finds Clinically Actionable Alterations

Lucid Diagnostics Raises $22M in Convertible Debt Refinancing

Medicover Genetics Receives IVDR Certification for Genetic Testing Reagent Kit

Final FDA Guidance Lays Path for Drugmakers to Establish Circulating Tumor DNA as Trial Endpoint

Multi-Ancestry Study Uncovers Genetic Contributors to Progressive Eye Disease